FENNEC PHARMACEUTICALS INC. Operating Expenses
FENNEC PHARMACEUTICALS INC. (FENC) reported Operating Expenses of $16.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- FENNEC PHARMACEUTICALS INC. operating expenses for the quarter ending 2026-06-30 was $16.14M, a 30.31% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. operating expenses for the quarter ending 2026-03-31 was $15.23M, a 59.29% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. operating expenses for the quarter ending 2025-12-31 was $16.33M, a 84.34% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. operating expenses for the quarter ending 2025-09-30 was $12.65M, a 3.90% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. operating expenses for fiscal 2025 was $50.92M, a 13.24% increase from fiscal 2024.
- FENNEC PHARMACEUTICALS INC. operating expenses for fiscal 2024 was $44.97M, a 32.18% increase from fiscal 2023.
- FENNEC PHARMACEUTICALS INC. operating expenses for fiscal 2023 was $34.02M, a 41.54% increase from fiscal 2022.
- FENNEC PHARMACEUTICALS INC. operating expenses for fiscal 2022 was $24.04M, a 39.57% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed | Operating Expenses 178 month | Operating Expenses 181 month | Operating Expenses 190 month | Operating Expenses 193 month | Operating Expenses 202 month | Operating Expenses 205 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $16.14M 10-Q · filed 2026-08-13 | $31.36M 10-Q · filed 2026-08-13 | $47.70M derived: sum of 3 quarters · filed 2026-08-13 | $60.35M derived: sum of 4 quarters · filed 2026-08-13 | ||||||||||
| 2026-03-31 | $15.23M 10-Q · filed 2026-05-14 | $31.56M derived: sum of 2 quarters · filed 2026-05-14 | $44.21M derived: sum of 3 quarters · filed 2026-05-14 | $56.59M derived: sum of 4 quarters · filed 2026-08-13 | ||||||||||
| 2025-12-31 | $16.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $28.98M derived: sum of 2 quarters · filed 2026-03-27 | $41.37M derived: sum of 3 quarters · filed 2026-08-13 | $50.92M 10-K · filed 2026-03-27 | ||||||||||
| 2025-09-30 | $12.65M 10-Q · filed 2025-11-13 | $25.04M derived: sum of 2 quarters · filed 2026-08-13 | $34.59M 10-Q · filed 2025-11-13 | $43.45M derived: sum of 4 quarters · filed 2026-08-13 | ||||||||||
| 2025-06-30 | $12.38M 10-Q · filed 2026-08-13 | $21.94M 10-Q · filed 2026-08-13 | $30.80M derived: sum of 3 quarters · filed 2026-08-13 | $42.98M derived: sum of 4 quarters · filed 2026-08-13 | ||||||||||
| 2025-03-31 | $9.56M 10-Q · filed 2026-05-14 | $18.42M derived: sum of 2 quarters · filed 2026-05-14 | $30.59M derived: sum of 3 quarters · filed 2026-05-14 | $42.90M derived: sum of 4 quarters · filed 2026-05-14 | ||||||||||
| 2024-12-31 | $8.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $21.04M derived: sum of 2 quarters · filed 2026-03-27 | $33.34M derived: sum of 3 quarters · filed 2026-03-27 | $44.97M 10-K · filed 2026-03-27 | ||||||||||
| 2024-09-30 | $12.18M 10-Q · filed 2025-11-13 | $24.48M derived: sum of 2 quarters · filed 2025-11-13 | $36.11M 10-Q · filed 2025-11-13 | $47.66M derived: sum of 4 quarters · filed 2025-11-13 | ||||||||||
| 2024-06-30 | $12.30M 10-Q · filed 2025-08-14 | $23.93M 10-Q · filed 2025-08-14 | $35.49M derived: sum of 3 quarters · filed 2025-08-14 | $43.02M derived: sum of 4 quarters · filed 2025-08-14 | ||||||||||
| 2024-03-31 | $11.63M 10-Q · filed 2025-05-14 | $23.19M derived: sum of 2 quarters · filed 2025-05-14 | $30.72M derived: sum of 3 quarters · filed 2025-05-14 | $38.71M derived: sum of 4 quarters · filed 2025-05-14 | ||||||||||
| 2023-12-31 | $11.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $19.09M derived: sum of 2 quarters · filed 2025-03-26 | $27.08M derived: sum of 3 quarters · filed 2025-03-26 | $34.02M 10-K · filed 2025-03-26 | $32.76M 10-K · filed 2024-03-29 | |||||||||
| 2023-09-30 | $7.53M 10-Q · filed 2024-11-08 | $7.20M 10-Q · filed 2023-11-09 | $15.52M derived: sum of 2 quarters · filed 2024-11-08 | $22.47M 10-Q · filed 2024-11-08 | $21.90M 10-Q · filed 2023-11-09 | $30.05M derived: sum of 4 quarters · filed 2024-11-08 | ||||||||
| 2023-06-30 | $7.99M 10-Q · filed 2024-08-13 | -$7.84M 10-Q · filed 2023-08-07 | $14.94M 10-Q · filed 2024-08-13 | $14.70M 10-Q · filed 2023-08-07 | $22.52M derived: sum of 3 quarters · filed 2024-08-13 | $30.42M derived: sum of 4 quarters · filed 2024-08-13 | ||||||||
| 2023-03-31 | $6.95M 10-Q · filed 2024-05-14 | $6.85M 10-Q · filed 2023-05-12 | $14.53M derived: sum of 2 quarters · filed 2024-05-14 | $22.43M derived: sum of 3 quarters · filed 2024-05-14 | $17.42M derived: sum of 4 quarters · filed 2024-05-14 | |||||||||
| 2022-12-31 | $7.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $15.48M derived: sum of 2 quarters · filed 2024-03-29 | $10.47M derived: sum of 3 quarters · filed 2024-03-29 | $24.04M 10-K · filed 2024-03-29 | ||||||||||
| 2022-09-30 | $7.90M 10-Q · filed 2023-11-09 | $2.89M derived: sum of 2 quarters · filed 2023-11-09 | $16.45M 10-Q · filed 2023-11-09 | |||||||||||
| 2022-06-30 | -$5.01M 10-Q · filed 2023-08-07 | $8.55M 10-Q · filed 2023-08-07 | ||||||||||||
| 2022-03-31 | $3.55M 10-Q · filed 2023-05-12 | |||||||||||||
| 2021-12-31 | $17.22M 10-K · filed 2023-03-29 | |||||||||||||
| 2021-03-31 | $4.92M 10-Q · filed 2021-05-13 | |||||||||||||
| 2020-12-31 | $18.05M 10-K · filed 2022-02-28 | |||||||||||||
| 2020-03-31 | $3.83M 10-Q · filed 2021-05-13 | |||||||||||||
| 2019-12-31 | $13.01M 10-K · filed 2021-03-30 | |||||||||||||
| 2013-09-30 | $51.00K 10-Q · filed 2013-11-18 | $978.00K derived: sum of 2 quarters · filed 2013-11-18 | $1.51M 10-Q · filed 2013-11-18 | $115.76M 10-Q · filed 2013-11-18 | ||||||||||
| 2013-06-30 | $927.00K 10-Q · filed 2013-08-09 | $1.46M 10-Q · filed 2013-08-09 | $115.71M 10-Q · filed 2013-08-09 | |||||||||||
| 2012-09-30 | $630.00K 10-Q · filed 2013-11-18 | $1.88M derived: sum of 2 quarters · filed 2013-11-18 | $2.50M 10-Q · filed 2013-11-18 | $113.12M 10-Q · filed 2012-11-14 | ||||||||||
| 2012-06-30 | $1.25M 10-Q · filed 2013-08-09 | $1.87M 10-Q · filed 2013-08-09 | $112.49M 10-Q · filed 2012-08-13 | |||||||||||
| 2011-09-30 | $944.00K 10-Q · filed 2012-11-14 | $1.52M derived: sum of 2 quarters · filed 2012-11-14 | $2.54M 10-Q · filed 2012-11-14 | $109.72M 10-Q · filed 2011-11-14 | ||||||||||
| 2011-06-30 | $572.00K 10-Q · filed 2012-08-13 | $1.59M 10-Q · filed 2012-08-13 | $108.78M 10-Q · filed 2011-08-15 | |||||||||||
| 2010-09-30 | $917.00K 10-Q · filed 2011-11-14 | $3.42M derived: sum of 2 quarters · filed 2011-11-14 | $3.79M 10-Q · filed 2011-11-14 | |||||||||||
| 2010-06-30 | $2.50M 10-Q · filed 2011-08-15 | $2.87M 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |